Trial Profile
A phase 2a TDM-guided clinical study on the safety and efficacy of mebendazole in patients with advanced gastrointestinal cancer or cancer of unknown origin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Mebendazole (Primary)
- Indications Adenocarcinoma; Gastrointestinal cancer; Liver cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms RepoMeb
- Sponsors Repos Pharma
- 07 Apr 2022 Status changed from discontinued to completed.
- 18 Jan 2020 Status changed from recruiting to discontinued.
- 19 Apr 2018 New trial record